US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Nutriband Inc. - Common Stock (NQ:NTRB)

7.280 -0.080 (-1.09%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nutriband Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development
Via Investor Brand Network
Topics Government
News headline image
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology 
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
From Nutriband Inc.
Via GlobeNewswire
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21
Via Investor Brand Network
News headline image
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
Nutriband Inc. (NASDAQ:NTRB) Targets the Opioid Safety Gap in a Multi-Billion-Dollar Market
Via AB Newswire
News headline image
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl
Via Investor Brand Network
Topics Intellectual Property
News headline image
Nutriband Co-Founder Gareth Sheridan Returns as CEO
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress
Via Investor Brand Network
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL
Via Investor Brand Network
News headline image
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Via Investor Brand Network
News headline image
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
From Nutriband Inc.
Via GlobeNewswire
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at MicroCap Rodeo Conference
Via Investor Brand Network
News headline image
11 Company Presentations Today at The MicroCap Rodeo Conference
Via ACCESS Newswire
News headline image
Nutriband Inc. to Present at the MicroCap Rodeo Conference
Thursday, September 25, 2025 in New York City 
From Nutriband Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology
Via Investor Brand Network
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
Via Investor Brand Network
News headline image
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
From Nutriband Inc.
Via GlobeNewswire
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)
Via Investor Brand Network
Topics Intellectual Property
Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >